Skip to NavigationSkip to content

Manufacturing and Production

Top Ten most popular articles on this week

It's Friday, so it's time to bring you another run-down of the top ten most popular articles with's readers this week.

Despite a drought of mergers and acquisitions throughout 2017, rumours are already circulating on what deals may occur this year, and among them, Celgene is expected to attempt to acquire Juno Therapeutics and the valuable CAR T therapy it is developing for $7 billion.

Riding the wave: The FDA and real world evidence

Published on 18/01/18 at 10:23am

Following on from this week's earlier piece on real world evidence, Jacqueline Corrigan-Curay, Director of CDER's Office of Medical Policy at the FDA, tells Pharmafocus how the US regulator has and continues to embrace the technology.

GSK Consumer Healthcare announces new Asia Pacific Regional Head

Published on: 16/01/18

GlaxoSmithKline’s Consumer Healthcare business has revealed that Filippo Lanzi is to take over as Regional Head of Asia Pacific, overseeing operations in 23 countries. He will also take on membership of GSK’s consumer healthcare strategic leadership team and Singapore country board.

He replaces Zubair Ahmed, who assumes the role of Non-Executive Chairman of India Board.

Hikma bring in new CSO

Published on: 16/01/18

Hikma Pharmaceuticals has announced that Surendera Tyagi is being brought in to join the company as Group Chief Scientific Officer and Global Head of R&D. The company revealed that Tyagi’s principal role will be to inject some life into the group’s non-injectables business during his first year with Hikma.

Boehringer's Gilotrif approved in US for lung cancer with non-resistant EGFRs

Boehringer Ingelheim is celebrating the FDA’s decision to expand the indication of its lung cancer drug Gilotrif (afatinib) to include the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have non-resistant epidermal growth factor receptor (EGFRs).

The US regulator’s decision was based on positive trial data which included the investigation of patients with the EGFR mutations L861Q, G719X and S768I.

Mundipharma signs Chinese licensing and distribution agreement with Grünenthal

US-based firm Mundipharma is set to take over commercialisation and distribution duties for the analgesic Tramal (tramadol) in China on behalf of Grünenthal, it has emerged.

Mundipharma has signed a licensing and distribution deal with the German pharmaceutical firm which covers a number of forms of the medicine, including Tramal sustained release tablets, immediate release capsules and a post-operation intravenous formulation know3n as patient controlled intraveneous analgesia (PCIA). It will assume the duties from 1 May this year.

Novartis debuts new data showing Cosentyx's superiority over Janssen's Stelara in psoriasis

Novartis has lifted the curtain on new data comparing the efficacy of Cosentyx (secukinumab) to Janssen’s Stelara (ustekinumab) in achieving skin clearance in patients with moderate-to-severe plaque psoriasis after 12 weeks.  

FDA expands indication of Teva's Trisenox for acute promyelocytic leukaemia

Teva has announced that its Trisenox (arsenic trioxide) injection has been awarded US approval from the FDA in combination with tretinoin for the treatment of newly-diagnosed low-risk acute promyelocytic leukaemia (APL) in adult patients whose APL is characterised by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.

Asthma carves $82 billion out of US economy every year

A study created by researchers at the Centers for Disease Control and Prevention has estimated that asthma is costing the US economy $81.9 billion each year.

The findings were an extrapolation from close to 214,000 respondents over a six-year period, within with which 10,237 individuals were identified as being treated for asthma.

Asthma sufferers were identified by having at least one medical encounter for asthma or filling in a prescription for asthma medicine once a year.

Seizing opportunities in the next steps for real world evidence

Published on 15/01/18 at 11:12am

Real world evidence is high on the agenda at many conferences, as people mull over the possibilities that it may hold for changing the way we track a particular medicine's efficacy. Matt Fellows has compiled some of the latest thought leadership on the challenges that lie ahead for wider adoption of the technology.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches